685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER, NJ
Yarrow Bioscience, Inc. Enters Underwriting Agreement for $161.8 Million Offe...
Advances YB-101 for Treatment of Autoimmune Thyroid Diseases
Amended material disclosure
Other Events
Earnings Release
Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger
VYNE Stockholders Approve Merger with Yarrow Bioscience, Inc.
Bringing Life Into Balance July 2026
Q2
FY 2024
Q3
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
S-4/A
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload